PureTech Announces Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

PureTech Health has announced the publication of Phase 2b ELEVATE IPF trial results in The American Journal of Respiratory and Critical Care Medicine. The results informed the design of the upcoming Phase 3 SURPASS-IPF trial, which will evaluate deupirfenidone 825 mg TID monotherapy compared to pirfenidone 801 mg TID monotherapy. The ELEVATE IPF trial demonstrated that deupirfenidone significantly slowed lung function decline versus placebo and approached the rate expected with healthy aging. The Phase 3 trial is expected to initiate in the first half of 2026.